M&A Deal Summary

Axsome Acquires Jazz Pharmaceuticals - Sunosi

On March 28, 2022, Axsome acquired life science company Jazz Pharmaceuticals - Sunosi from Jazz Pharmaceuticals for 53M USD

Acquisition Highlights
  • This is Axsome’s 1st transaction in the Life Science sector.
  • This is Axsome’s largest (disclosed) transaction.
  • This is Axsome’s 1st transaction in Ireland.

M&A Deal Summary
Date 2022-03-28
Target Jazz Pharmaceuticals - Sunosi
Sector Life Science
Buyer(s) Axsome
Sellers(s) Jazz Pharmaceuticals
Deal Type Divestiture
Deal Value 53M USD

Target

Jazz Pharmaceuticals - Sunosi

Dublin, Ireland
Jazz Pharmaceuticals' Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).

Search 192,611 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Axsome

New York, New York, United States

website

Category Company
Founded 2012
Sector Life Science
Employees108
DESCRIPTION

Axsome is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through the development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. Axsome was founded in 2012 and is based in New York City.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (Ireland) 1 of 1
Year (2022) 1 of 1
Size (of disclosed) 1 of 1

Seller(S) 1

SELLER

Jazz Pharmaceuticals

Dublin 4, Ireland

website

Category Company
Founded 2003
Sector Life Science
Employees1,940
Revenue 2.4B USD (2020)
DESCRIPTION
Jazz Pharmaceuticals office in Palo Alto, California.
Jazz Pharmaceuticals office in Palo Alto, California.

Jazz Pharmaceuticals is a specialty biopharmaceutical company that identifies, develops and commercializes products to address unmet medical needs in focused therapeutic areas. Jazz Pharmaceuticals was founded in 2003 and is based in Dublin, Ireland.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Divestiture) 2 of 2
Country (Ireland) 1 of 1
Year (2022) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-02-03 GW

Cambridge, United Kingdom

GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX® (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX® for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC.

Buy $6.7B
Mergr

Product

Company

Legal